I'm LongbridgeAI, I can summarize articles.JPMorgan released a research report stating that the updated US nucleic acid screening policy faced by GENSCRIPT BIO (01548.HK) +2.860 (+9.132%) Short selling $193.98M; Ratio 20.813% is a manageable issue rather than a fundamental demand or market access risk. The broker maintained its Overweight rating and HKD41 TP on the stock.
The broker noted that the policy is not entirely new, as it is based on the 2023 US Department of Health and Human Services screening guidance and the 2024 White House Office of Science and Technology Policy framework. The policy requires US customers receiving federal funding to procure synthetic nucleic acids and benchtop synthesis equipment from "compliant" suppliers, while suppliers must not be located in or controlled by "covered countries" including China. The broker believes that, as a founding member of the International Gene Synthesis Consortium, GENSCRIPT BIO has promoted responsible gene synthesis practices for years and self-certified compliance with the US nucleic acid synthesis screening framework in 2024. In addition, revenue from federally funded US gene synthesis projects is expected to be relatively small, as most commercial US pharmaceutical and biotechnology companies do not receive substantial federal research funding. Therefore, the impact on GENSCRIPT BIO's gene synthesis business is expected to be limited.
The broker added that while the policy tightens procurement rules, it does not prohibit foreign suppliers, and compliance requirements will be implemented in phases. The key issue lies in certification and enforcement rather than policy direction. As suppliers must not be located in or controlled by "covered countries" including China, GENSCRIPT BIO's US entities may need to undertake more gene synthesis projects from other locations. (ad/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-11-10 12:25.)
